Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KATERZIA vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KATERZIA (bosentan) is an endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. This inhibits ET-1-mediated vasoconstriction and smooth muscle proliferation, reducing pulmonary vascular resistance and pulmonary arterial pressure.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and decrease clinical worsening in patients with WHO class II–IV symptoms,Off-label: Treatment of digital ulcers in systemic sclerosis; prevention of recurrence of digital ulcers; management of inoperable chronic thromboembolic pulmonary hypertension
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
5 mg orally once daily for 21 days, then 7 days off, repeated in 28-day cycles.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. In patients with hypertension or hepatic impairment, half-life may be prolonged up to 15-20 hours, necessitating dose adjustment.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily metabolized by CYP2C9 and CYP3A4 to three major metabolites (Ro 48-5033, Ro 47-8634, Ro 64-1056). Induces CYP2C9 and CYP3A4; also induces CYP2C19.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal elimination accounts for approximately 60-80% of the administered dose, predominantly as unchanged drug via glomerular filtration and active tubular secretion. Biliary/fecal excretion is minimal, <5%.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
Approximately 95-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High binding limits tissue distribution and affects free drug concentration.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.7-1.2 L/kg (range 50-80 L for a 70 kg adult), indicating moderate tissue distribution beyond plasma volume.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral bioavailability is approximately 30-40% due to extensive first-pass hepatic metabolism. Food may reduce bioavailability by 20-30%, so dosing should be consistent with respect to meals.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg orally once daily for 21 days, then 7 days off. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and efficacy not established in pediatric patients.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
No specific dose adjustment required; monitor for adverse events due to potential age-related renal and hepatic decline.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
WARNING: HEPATOTOXICITY. Bosentan can cause serious hepatic injury, including acute liver failure, requiring baseline and monthly monitoring of liver enzymes. Discontinue if ALT/AST >3x ULN accompanied by symptoms or bilirubin >2x ULN.
None
Hepatotoxicity (monitor LFTs monthly), hepatorenal syndrome; peripheral edema; fluid retention; may cause hypotension; pulmonary veno-occlusive disease (PVOD) may cause pulmonary edema; decreases hemoglobin and hematocrit (monitor at 1 and 3 months, then every 3 months); decreases sperm count; reduces efficacy of hormonal contraceptives (use alternative contraception); caution in hepatic impairment (Child-Pugh Class A; contraindicated in moderate to severe impairment); caution in elderly; not recommended in patients with severe anemia.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Absolute: Hypersensitivity to bosentan or any component; moderate to severe hepatic impairment (Child-Pugh Class B or C); baseline AST/ALT >3× ULN; concomitant use with cyclosporine A (increases bosentan levels and hepatotoxicity); concomitant use with glyburide (increases risk of liver enzyme elevations); pregnancy (teratogenic in animals – can cause birth defects; must exclude pregnancy before initiation and monthly thereafter).
None
Take with food to improve tolerability and reduce gastrointestinal adverse effects. Avoid grapefruit juice as it may increase treprostinil exposure. Avoid alcohol as it may exacerbate vasodilation and hypotension.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
Pregnancy Category C. First trimester: animal studies show fetal toxicity; no adequate human data. Second/third trimester: may cause fetal renal impairment, oligohydramnios, and skull ossification defects due to direct renin-angiotensin system inhibition.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
No human data; M/P ratio unknown. Excreted in rat milk. Due to potential risk of hypotension and renal impairment in nursing infants, discontinue drug or breastfeeding, considering importance to mother.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
No specific dose adjustments established for pregnancy. However, due to increased plasma volume, efficacy may be reduced; monitor therapeutic response. Contraindicated in pregnancy; avoid use.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
KATERZIA (oral treprostinil) is a prostacyclin analogue used for pulmonary arterial hypertension (PAH). Monitor for prostacyclin-related side effects (headache, nausea, diarrhea, jaw pain, flushing). Dose titration is critical; increase by 0.25 mg BID or 0.125 mg TID every 3-4 days as tolerated. Avoid abrupt discontinuation due to risk of rebound pulmonary hypertension. Use with caution in patients with hepatic impairment; reduce starting dose in moderate impairment.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take KATERZIA exactly as prescribed, with food to reduce gastrointestinal side effects.,Do not stop taking this medication suddenly; consult your doctor before making any changes.,Common side effects include headache, nausea, diarrhea, jaw pain, and flushing; report severe or persistent symptoms.,Avoid alcohol and grapefruit juice as they may interact with the medication.,Store tablets in the original container at room temperature, away from moisture and light.,If you miss a dose, skip it and take the next dose at the scheduled time; do not double dose.,Inform your healthcare provider of all medications you are taking, especially antihypertensives, anticoagulants, and NSAIDs.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KATERZIA vs AMVAZ, answered by our medical review team.
KATERZIA is a Calcium Channel Blocker that works by KATERZIA (bosentan) is an endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. This inhibits ET-1-mediated vasoconstriction and smooth muscle proliferation, reducing pulmonary vascular resistance and pulmonary arterial pressure.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KATERZIA and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KATERZIA is: 5 mg orally once daily for 21 days, then 7 days off, repeated in 28-day cycles.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KATERZIA and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KATERZIA is classified as Category C. Pregnancy Category C. First trimester: animal studies show fetal toxicity; no adequate human data. Second/third trimester: may cause fetal renal impairment, oligohydramnios, and sk. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.